Background and Aims: Big data analytics leverage patterns in data to harvest valuable information, but are rarely implemented in clinical care. Optimising thiopurine therapy for inflammatory bowel disease [IBD] has proved difficult. Current methods using 6-thioguanine nucleotide [6-TGN] metabolites have failed in randomized controlled trials [RCTs], and have not been used to predict objective remission [OR]. Our aims were to: 1) develop machine learning algorithms [MLA] using laboratory values and age to identify patients in objective remission on thiopurines; and 2) determine whether achieving algorithm-predicted objective remission resulted in fewer clinical events per year. Methods: Objective remission was defined as the absence of objective evidence of intestinal inflammation. MLAs were developed to predict three outcomes: objective remission, nonadherence, and preferential shunting to 6-methylmercaptopurine . The performance of the algorithms was evaluated using the area under the receiver operating characteristic curve [AuROC]. Clinical event rates of new steroid prescriptions, hospitalisations, and abdominal surgeries were measured. Results: Retrospective review was performed on medical records of 1080 IBD patients on thiopurines. The AuROC for algorithm-predicted remission in the validation set was 0.79 vs 0.49 for 6-TGN. The mean number of clinical events per year in patients with sustained algorithm-predicted remission [APR] was 1.08 vs 3.95 in those that did not have sustained APR [p < 1 x 10
Introduction
The use of big data algorithms in the business world has proved to be remarkably valuable. The results of these machine learning approaches have disrupted markets and produced enormous revenues. [1] [2] [3] Machine learning is a family of approaches used to evaluate large datasets for patterns that can predict outcomes, including random forest, boosting, and support vector machines. 4, 5 These approaches are commonly used in business but are now being used in medicine. 6, 7 A recent American Gastroenterology Association [AGA] perspective article suggests there is a great opportunity and potential for the use of big data algorithms in gastroenterology. 8 Thiopurines are widely used immunomodulators for the treatment of ulcerative colitis [UC] and Crohn's disease [CD] in inflammatory bowel disease [IBD] patients. 9 Thiopurines can induce immune suppression, clinical and biological remission, and are steroid-sparing agents, 10, 11 but have a narrow therapeutic index. Dose optimisation of thiopurines using 6-thioguanine nucleotide metabolite measurement has failed in two published randomized controlled trials [RCTs] and showed low accuracy for clinical remission in a meta-analysis. [12] [13] [14] Thiopurine metabolites have also never been used to predict objective remission [OR, the absence of intestinal inflammation]. Physicians prescribing thiopurines for immune suppression have traditionally relied on patterns in the complete blood count and chemistry to monitor clinical response and to titrate dosing of thiopurines. We hypothesised that machine learning algorithms could identify patterns of laboratory values in IBD patients on thiopurine medications, which are consistent with immune suppression that would predict which patients are most likely to achieve objective remission.
Machine learning algorithms [MLA] to monitor clinical response to thiopurines have been shown to be more accurate than 6-TGN levels at predicting clinical response. 15 Thiopurine monotherapy still remains the primary method of immunosuppression for IBD throughout the world, but success in achieving objective remission with thiopurines is limited. 16 The previously published thiopurine MLAs predicted clinical response based on subjective measures. The accumulating evidence that objective remission in IBD produces better clinical outcomes has led to a change in endpoints of clinical trials in IBD, to require objective evidence of control of inflammation such as endoscopic scoring rather than the Crohn's Disease Activity Index. We therefore elected to use any evidence of inflammation from endoscopy, 
Methods

Patient population
The study sample included all IBD patients taking thiopurines who had a complete blood count with differential 
Independent predictor variables
Independent predictor variables included values from the CBCD, values from the COMP, and patient age. Patient demographic information and laboratory values were obtained by electronic data query. The patient's age was calculated as the exact number of years between the date of birth and the date of the laboratory draw.
Alternative predictors of objective remission
The 6-TGN level was evaluated as a predictor of objective remission, as it is marketed as an effective way to monitor patients on thiopurines. In addition, many practitioners use elevations in the mean corpuscular volume [MCV] and reductions in the white blood cell count [WBC] as inexpensive monitoring tests during thiopurine use. We also evaluated the comparative accuracy of the MCV/WBC ratio as a simple predictor of objective remission. 
Statistical modelling and analysis
Random forest [RF] machine learning 4 was used to develop algorithms for the three dependent variables: objective remission, nonadherence, and shunting. Random forest is a tree-based statistical method used to build prediction models. For this method, each decision tree considers a random subset of predictor variables at each decision point and ultimately forms a prediction. The predictions from each tree can be thought of as a 'vote'. When the votes from all of the trees are combined, the most popular vote is considered to be the final predicted outcome. For ThioMon v2, 1000 trees were built to form the final predicted outcome and also to identify which variables contributed most to the accuracy of this model. To evaluate the performance of the random forest model, the out-of-bag [OOB] predictions on all observations and the area under the receiver operating characteristic curve [AuROC] were used. Because the out-of-bag observations were not used in the fitting of the trees, the out-of-bag observations served as the validation dataset. In addition to using the OOB observations, two alternative validation methods were also used to assess the robustness of the model: 1] the original data were split into new training [~ 70%] and validation [~ 30%] sets based on individuals, i.e. all observations corresponding to one individual were assigned to either the training or the validation set; and 2] the training and validation split was based on the visit time, i.e. different observations corresponding to the same individual were split into training and validation such that earlier visits belong to the training set and later visits belong to the validation set, as the algorithm is predicting future outcomes. The AuROC curves for OR produced by the 6-TGN metabolite levels and the MCV/WBC ratio were also compared with the AuROC of the random forest algorithm to predict objective remission based on the laboratory tests and age, with the R package pROC. 17 All random forest models were built in the statistical language, R [version 2.8.1], with the package randomForest. 4, 5 by YW and JZ. Two-sided p-values less than 0.05 were considered statistically significant. Brier scores were calculated as the mean square of the difference between the true outcome and the fraction of out-of-bag votes from the random forest. 18 
Annual clinical event rates
A cutoff for the algorithm to predict remission was identified to provide an optimal balance of sensitivity and specificity. Patients with predicted values above this threshold were considered to be in an algorithm-predicted remission [APR] state. Patients with repeated measurements above the APR threshold for ≥ 30 days were considered to have sustained APR. Clinical event rates, as defined by new steroid prescriptions, hospitalisations, and abdominal surgeries per year of follow-up [Supplementary Table 2, available as Supplementary data at ECCO-JCC online], were compared between those with sustained APR and those without sustained APR with Student's t test. These annual event rates were also compared with a paired t test between two periods of time within a subset of patients who did not have sustained APR for a period, followed by a period of sustained APR.
Sensitivity analyses
The effects of two different splits of the dataset to form separate training and validation sets were assessed with: 1] 70:30 split accounting for individuals; and 2] 70:30 split by time being tested. In order to determine whether there were any significant differences in the predictive accuracy of the model in patients with UC or CD, a sensitivity analysis was performed evaluating the AuROC for UC vs CD to determine whether it was valid to pool UC and CD in the analysis. In order to evaluate whether the different measures of inflammation used to determine objective remission were equally valid, we performed analyses of objective remission using a 'leave one out' strategy, by defining objective remission without using [in turn] CRP, MRI, endoscopy, and cases determined by laboratory results only. We then determined whether the change in definition substantially changed the accuracy of the models. Table 1 describes the characteristics of our total study sample by individual patient, which included 3263 cases, in a total of 1080 individuals. The application of the criteria for the assessment of objective remission yielded a study population for the objective remission endpoint of 1837 objective remission cases and 1426 non-OR cases (Figure 1 ). Of the 3263 cases from our total study sample, 509 cases had measurements of thiopurine metabolites and were included in the nonadherence study sample and the shunting study sample. The nonadherence study sample was supplemented with 608 IBD patients with measurements of thiopurine metabolites from our previous ThioMon dataset (ThioMon v1), 15 for a total of 1117 cases and 603 individuals [Supplementary Figure 1A , available as Supplementary data at ECCO-JCC online]. The shunting study sample was supplemented with 555 unique cases from ThioMon 
Results
Predicting objective remission
A machine learning algorithm was developed to predict objective remission, using laboratory values and patient age, and this MLA for APR differentiated objective remission from non-remission in the validation dataset, with an area under the AuROC of 0.79 (95% confidence interval [CI], 0.78-0.81) as seen in Figure 2A . In Figure 2B , the variable importance graph describes the relative contribution, as a percentage, of each predictor variable used in the model. The total contributions of the all the predictor variables add up to 100%. The five most important variables include: haemoglobin, lymphocytes, haematocrit, neutrophils, and platelets. In a sensitivity analysis, similar results based on individual and visiting time splits were obtained, and are presented in Supplementary Table 3 . Brier scores were evaluated as a measure of performance, which are used when the outcome of interest is categorical instead of continuous. 15 Brier scores can range from 0 to 1, with lower scores being consistent with more accurate and better model performance. 19 To illustrate how the individual variables relate to the objective remission endpoint, partial dependence plots for predicting objective remission are provided in Supplementary  Figure 2 .
Predicting nonadherence
A second random forest algorithm, using laboratory values and patient age, differentiated thiopurine adherence from nonadherence with an AuROC of 0.84 [95% CI, 0.79-0.89], shown in Figure 2C . The five most important variables for this algorithm include: red cell distribution width, mean corpuscular volume, mean platelet volume, haematocrit, and mean corpuscular haemoglobin. The proportional importance of each input variable in the random forest model for nonadherence is shown in Figure 2D . 
Predicting shunting to 6-MMP
A third random forest algorithm, using laboratory values and patient age, differentiated thiopurine shunters from non-shunters with an AuROC of 0.78 [95% CI, 0.74-0.82] [ Figure 2E ]. The five most important variables for this algorithm include: alanine transaminase [ALT], mean platelet volume, age, creatinine, and alkaline phosphatase. The proportional importance of each input variable in the random forest model for shunting is shown in Figure 2F .
Sustained algorithm-predicted remission and annual clinical event rates
An optimal cutoff score [0.564] from our machine learning algorithm to predict remission, that balanced sensitivity and specificity for objective remission, was used to identify which patients achieved algorithm-predicted remission on thiopurines. A total of 274 subjects with sustained algorithm-predicted remission were selected, and their annual clinical event rates were compared with those of 235 patients without sustained algorithm-predicted remission, as defined by our MLA cutoff. The demographics of these subjects are described in Supplementary Table 3 , available as Supplementary data at ECCO-JCC online. As seen in Figure 3 , the annual clinical event rate in patients with sustained algorithm-predicted remission was 1.08 compared with 3.95 in those without sustained algorithmpredicted remission [p = 2 × 10 
Achieving immunosuppression and clinical event rates
It is possible that the subjects who achieved immunosuppression were simply more responsive to thiopurine therapy, and those who failed were unlikely to ever respond to thiopurines; if this were the case, the MLA for APR would simply be identifying subjects' ability to respond to thiopurines. We therefore identified an additional 31 patients, representing 32 cases [one patient had four discrete intervals during the study period], with an initial period without sustained algorithm-predicted remission, followed by a subsequent period with sustained algorithm-predicted remission. The demographics of these subjects are described in Supplementary Table 3 ; 50% of these patients had a thiopurine dose increase [Supplementary Table 4 , available as Supplementary data at ECCO-JCC online]. The remainder achieved APR for unclear reasons, though undocumented improved adherence may have contributed.
We evaluated whether these subjects had a change in their clinical outcomes between these two periods. In those patients who achieved APR, the rate of steroid prescriptions decreased by 2. This study used composite measures of objective remission; however, not all measures of objective remission were used in all patients. This suggests that there could be heterogeneity in the objective remission cohort, which could threaten the generalisability of the conclusions. Table 2 shows the distribution of the various measurements used to determine objective remission. A sensitivity analysis in Table 3 . Misclassification table comparing the MLA, the MCV/WBC ratio, and 6-TGN for the outcome of objective remission, along with Brier scores for each model or predictor. The optimal cutoff for 6-TGN in our dataset was 173.5. We also present the traditional cut-off value of 235 for comparison. Brier scores are an overall measure of model performance that captures both calibration and discrimination. Brier scores can range from 0 to 1, with lower Brier scores being consistent with more accurate and better model performances. Misclassification table also includes the MLA for nonadherence and the MLA for shunting.
Prediction tool Cutoff
Objective Table 4 ]. It should also be noted that imaging data, which includes MRI and CT, only provided the assessment of objective remission in a small number of patients and were never used as the sole method to identify patients in objective remission. Some of the cases determined to be in objective remission included patients on steroid medication. The possibility that steroids may interfere with the algorithm was explored in our first publication and it was found that when patients on steroids were excluded, the AuROC only reduced a small amount from 0.86 to 0.81 [95% CI, 0.72-0.89]. 9 To determine an approximate amount, 13% of objective remission cases were reviewed and it was determined that 22% of these cases in objective remission were patients on steroid medication for IBD.
Discussion
Experts in inflammatory bowel disease have long used thiopurine therapy without metabolite monitoring, 19 and relied on patterns in the complete blood count and chemistries to monitor their patients. Random forest modelling applied to standard laboratory values can identify patterns of laboratory values consistent with immunosuppression with thiopurines, 15 and in this manuscript we demonstrate that achieving these patterns is associated with dramatic improvement in important clinical outcomes.
This pattern of laboratory values likely reflects the actions of thiopurines on the bone marrow, the blood, the liver, the kidney, and metabolites in plasma which affect the immune responses driving inflammation in IBD. These changes in laboratory values are associated with biological response to thiopurines, but the data we present cannot be considered sufficient proof of a causal pathway. The elevation in eosinophils associated with biological remission during thiopurine therapy might indicate an effect on Th2 pathways, 20 and the rise in alkaline phosphatase 21 associated with biological remission might be due to effects on bone marrow or the liver. It is impossible to establish causality with retrospective data.
In addition, a portion of the patients with initial poor response to thiopurines were later able to achieve sustained algorithm-predicted remission through thiopurine dose and regimen adjustment, and this change was associated with significant improvements in clinical outcomes. While dose adjustment can produce sustained algorithmpredicted remission in many IBD patients, this MLA can also be used to identify patients who have maximized thiopurines (achieving algorithm-predicted remission) but still have inflammation, allowing them to rapidly move on to more effective therapies. The additional two MLAs, which identify patients who are nonadherent to therapy and those who shunt to the 6-MMP alternate metabolite pathway, add to the ability to monitor thiopurine therapy.
Limitations
The assessment of this machine learning algorithm to predict remission was limited to a single-centre population and retrospective data. A prospective RCT using this MLA to guide dose and regimen adjustment is needed for further evaluation. Even though a combination of different measurements was used to define objective remission in each case [i.e. CRP, ESR, FCP, MRI, CT, and/or endoscopy], running the MLA to predict remission while sequentially excluding each measurement produced similar results. Patients with ulcerative colitis and patients with Crohn's disease were pooled into one study sample, justified by similar accuracy of the algorithm AUC, are under the curve; CRP, C-reactive protein; MRI, magnetic resonance imaging; ESR, erythrocyte sedimentation rate; FCP, faecal calproectin; UC, ulcerative colitis; IBD, inflammatory bowel disease, OR, objective remission; NA, not available. *Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
